QuidelOrtho Corp. Aktie
36,80 €
Deine Einschätzung
QuidelOrtho Corp. Aktie
Was spricht für und gegen QuidelOrtho Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von QuidelOrtho Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | -0,54 % | 1,10 % | -15,60 % | -55,42 % | -45,74 % | -61,62 % | - |
Boston Scientific | 6,20 % | 7,03 % | 9,46 % | 47,34 % | 33,16 % | 94,00 % | 119,16 % |
Illumina Inc. | -1,62 % | 3,52 % | -9,79 % | -44,68 % | -10,69 % | -66,53 % | -59,30 % |
Waters Corp. | 0,75 % | -3,59 % | -9,97 % | 2,80 % | -4,01 % | 14,13 % | 55,73 % |
Kommentare
News
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test. This clearance allows